A Dendreon Inc., director, Gerardo Canet, sold over 200,000 stock options in the company on April 14. According to a filing with the SEC (Securities and Exchange Commission), the sale was made “pursuant to a Rule 10b5-1 trading plan.” Such trading plans are set up to defend company insiders from allegations of trading on insider information.

At 9 A:M ET on April 14 Dendreon’s CEO Mitchell Gold told investor analysts that Dendreon’s Provenge prostate cancer immunotherapy vaccine significantly prolongs survival in men with advanced metastatic prostate cancer. The results are “robust” and “unambiguous,” Gold stated.

“The successful outcome from the Phase 3 IMPACT study provides validation of the long-pursued goal of harnessing the human immune system against a patient’s own cancer,” the company stated in a press release April 14.

Mr. Canet’s SEC Form 4 filing was pointed out today by a member of the Dendreon message board at Investor Village. Members discussed whether Mr. Canet may have had a GTC or “Good ‘Til Canceled” order. This is “An order to buy or sell a security at a set price that is active until the investor decides to cancel it or the trade is executed. If an order does not have a good-’til-canceled instruction then the order will expire at the end of the trading day the order was placed.”

The SEC form in question states “The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.”

Dendreon’s prostate cancer vaccine significantly prolonged the overall survival among 500 men with advanced, metastic  prostate cancer  compared to a placebo, the company said Tuesday.

Results were “robust” and “unambiguous,” a spokesman said during today’s (Tues April 14) company broadcast conference call with biotech investment analysts.

“The successful outcome from the Phase 3 IMPACT study provides validation of the long-pursued goal of harnessing the human immune system against a patient’s own cancer,” Dendreon Chief Executive Mitchell Gold said in a statement.

“Survival is the gold standard outcome for oncology clinical trials, and overall survival was the primary endpoint of the IMPACT trial. The positive results from this landmark study provide confirmatory evidence demonstrating that treatment with PROVENGE may prolong survival,” Dendreon CEO Mitch Gold said.

The Seattle-based drugmaker said the phase III study of Provenge, known as IMPACT, met its primary endpoint with statistical significance. Details of the study are being withheld so that they can be presented at the American Urological Association’s Annual Meeting in Chicago on April 28.

Received from Halle Tecco, founder of YOGA BEAR, a non profit offering free yoga classes for cancer survivors:

Hello, my name is Halle and I’m the Executive Director of Yoga Bear, a non-profit that provides free yoga to cancer survivors across the US, through 125 partner yoga studios.  Most of our participants are female, and we’re trying to get more men involved! Since prostate cancer is so common for men, we wanted to reach out to your organization.  Could you please let your community know that we offer free passes to yoga studios for survivors interested in trying yoga?
Thank you,

http://www.yogabear.org/
blog.yogabear.org http://blog.yogabear.org

Abstracts for presentations to be made at this year’s annual general meeting of ASCO, The American Society of Clinical Oncology, are now online.

For prostate cancer abstracts go to Genitourinary Cancers Symposium and browse 226 titles under

Early/Localized disease, Locally Advanced/Recurrent/Advanced disease, and Biology

and 224  titles under

Epidemiology, Risk factors, Prevention, and Health Services Research

The meeting is scheduled for May 29-June 2 | Orlando, FL. The overall theme of this year’s meeting is “Personalizing Cancer Care.”

SEATTLE, April 13, 2009 -Dendreon Corporation (Nasdaq: DNDN) will host a conference call tomorrow, Tuesday, April 14, 2009, at 9:00 AM ET (6:00 AM PT) to review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE® (sipuleucel-T), the Company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

Those interested may access the call with the following information:

Time:         9:00 AM ET/6:00 AM PT

Date:          April 14, 2009

Dial-in:        1-877-419-6594 (domestic) or +1-719-325-4855 (international)

Webcast:       www.dendreon.com (homepage and investor relations section)

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 888-203-1112 or 719-457-0820 for international callers; the conference ID number is 8182435. The replay will be available from 12:00 pm ET on April 14, 2009 until midnight ET on April 16, 2009.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.